JP7560445B2 - 膵炎を処置するための方法 - Google Patents

膵炎を処置するための方法 Download PDF

Info

Publication number
JP7560445B2
JP7560445B2 JP2021513309A JP2021513309A JP7560445B2 JP 7560445 B2 JP7560445 B2 JP 7560445B2 JP 2021513309 A JP2021513309 A JP 2021513309A JP 2021513309 A JP2021513309 A JP 2021513309A JP 7560445 B2 JP7560445 B2 JP 7560445B2
Authority
JP
Japan
Prior art keywords
seq
antibody
pancreatitis
residues
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021513309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500382A (ja
JP2022500382A5 (https=
Inventor
ダニエル ディー． エングル，
デイビッド エー． トゥベソン，
Original Assignee
コールド スプリング ハーバー ラボラトリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コールド スプリング ハーバー ラボラトリー filed Critical コールド スプリング ハーバー ラボラトリー
Publication of JP2022500382A publication Critical patent/JP2022500382A/ja
Publication of JP2022500382A5 publication Critical patent/JP2022500382A5/ja
Application granted granted Critical
Publication of JP7560445B2 publication Critical patent/JP7560445B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021513309A 2018-09-10 2019-09-09 膵炎を処置するための方法 Active JP7560445B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729354P 2018-09-10 2018-09-10
US62/729,354 2018-09-10
PCT/US2019/050262 WO2020055768A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis

Publications (3)

Publication Number Publication Date
JP2022500382A JP2022500382A (ja) 2022-01-04
JP2022500382A5 JP2022500382A5 (https=) 2022-09-20
JP7560445B2 true JP7560445B2 (ja) 2024-10-02

Family

ID=69776851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513309A Active JP7560445B2 (ja) 2018-09-10 2019-09-09 膵炎を処置するための方法

Country Status (13)

Country Link
US (1) US12378320B2 (https=)
EP (1) EP3849605A4 (https=)
JP (1) JP7560445B2 (https=)
KR (1) KR20210073515A (https=)
CN (2) CN120267815A (https=)
AU (1) AU2019337564A1 (https=)
BR (1) BR112021004444A2 (https=)
CA (1) CA3112382A1 (https=)
CL (2) CL2021000585A1 (https=)
IL (1) IL281343A (https=)
MX (1) MX2021002761A (https=)
SG (1) SG11202102416SA (https=)
WO (1) WO2020055768A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002761A (es) 2018-09-10 2021-05-31 Cold Spring Harbor Laboratory Metodos para tratar la pancreatitis.
EP4277932A4 (en) * 2021-01-12 2024-06-12 Yeda Research and Development Co. Ltd Antibodies to cancer glycosylation and uses thereof
CA3214598A1 (en) * 2021-03-26 2022-09-29 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
US20250302409A1 (en) * 2024-03-26 2025-10-02 Hepatiq, Inc. Determining pancreas disease using functional imaging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530536A (ja) 2008-08-08 2011-12-22 イミューノメディクス、インコーポレイテッド 抗膵癌抗体
JP2016534735A (ja) 2013-08-26 2016-11-10 マブバクス セラピューティクス， インコーポレイテッド シアリル−Ｌｅｗｉｓ ａに対するヒト抗体をコードする核酸

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JPS63159763A (ja) * 1986-12-24 1988-07-02 Fujirebio Inc 逆受身凝集反応試薬
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CA2918223A1 (en) 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
MX2021002761A (es) 2018-09-10 2021-05-31 Cold Spring Harbor Laboratory Metodos para tratar la pancreatitis.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530536A (ja) 2008-08-08 2011-12-22 イミューノメディクス、インコーポレイテッド 抗膵癌抗体
JP2016534735A (ja) 2013-08-26 2016-11-10 マブバクス セラピューティクス， インコーポレイテッド シアリル−Ｌｅｗｉｓ ａに対するヒト抗体をコードする核酸

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKINOSOGLOU, Karolina and GOGOS, Charalambos，Immune-modulating therapy in acute pancreatitis: Fact or fiction，World J Gastroenterol.，2014年，vol. 20, no. 41，p. 15200-15215
DE MARCHI, Giulia et al.，Very high serum levels of CA 19-9 in autoimmune pancreatitis: Report of four cases and brief review of literature，Journal of Digestive Diseases，2016年，Volume17, Issue10，Pages 697-702
HABTEZION, Aida and ALGUI, Hana，Immune modulation in acute and chronic pancreatitis，Pancreapedia: Exocrine Pancreas Knowledge Base、[online］，2016年，検索日：２０２３年８月３日、URL=<https://www.pancreapedia.org/sites/default/files/Immune%20modulation%20in%20acute%20and%20chronic%20pancreatitis_0.pdf>
MINGHINI, Anita et al.，Specificity of elevated CA 19-9 levels in chronic pancreatitis，Surgery，1998年，Volume 124, Issue 1，Pages 103-105

Also Published As

Publication number Publication date
JP2022500382A (ja) 2022-01-04
US20220049011A1 (en) 2022-02-17
CN113056286A (zh) 2021-06-29
AU2019337564A1 (en) 2021-05-06
CN113056286B (zh) 2025-04-29
IL281343A (en) 2021-04-29
CL2021000585A1 (es) 2021-08-13
CL2022000091A1 (es) 2022-11-18
CN120267815A (zh) 2025-07-08
US12378320B2 (en) 2025-08-05
EP3849605A4 (en) 2022-06-15
KR20210073515A (ko) 2021-06-18
BR112021004444A2 (pt) 2021-06-01
CA3112382A1 (en) 2020-03-19
EP3849605A1 (en) 2021-07-21
MX2021002761A (es) 2021-05-31
WO2020055768A1 (en) 2020-03-19
SG11202102416SA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
US9316654B2 (en) TAZ/WWTR1 for diagnosis and treatment of cancer
JP7560445B2 (ja) 膵炎を処置するための方法
JP2013520958A (ja) 上皮間葉転換のバイオマーカーとしてａｘｌを使用する方法
US9790503B2 (en) VHZ for diagnosis and treatment of cancer
JP5756014B2 (ja) がんの診断および治療のためのｖｈｚ
SG187674A1 (en) Bard1 isoforms in lung and colorectal cancer and use thereof
US9758574B2 (en) Inflammatory disease treatment composition including anti-myosin regulatory light-chain polypeptide antibody
JP2021531007A (ja) Ｖｉｓｔａに対する受容体
CN116963779A (zh) 癌症免疫微环境的调节物质及其预防、诊断或治疗
CA3151199A1 (en) Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion
JP2022526131A (ja) 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
RU2839356C2 (ru) Способы лечения панкреатита
WO2010008084A1 (ja) 糖鎖認識受容体の新規用途
Gao et al. DysUFMylation reprograms immunosuppressive neutrophils to potentiate anti-PD-1 therapy in hepatocellular carcinoma
JP2014532408A (ja) ＵＳＰ２ａペプチドおよび抗体
WO2025217258A1 (en) Nptx1 antibodies
Mai Expression patterns of alpha-fetoprotein and phosphodiesterase 4D in canine mammary tumors
WO2024254596A9 (en) Compositions and methods for detection of aberrant cdk5 expression
JP2021097682A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
Englert A pathophysiologic evaluation of the receptor for advanced glycation end products (RAGE) in the lung
WO2007037538A1 (ja) Ｓｐｏ１１遺伝子の治療的又は診断的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240919

R150 Certificate of patent or registration of utility model

Ref document number: 7560445

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150